Advertisement

Clinical Drug Investigation

, Volume 27, Supplement 1, pp 15–22 | Cite as

Are there any Differences among Non-Steroidal Anti-Inflammatory Drugs? Focus on Nimesulide

  • Franco Dallegri
  • Luciano Ottonello
Article

Abstract

Although the efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory, analgesic and antipyretic agents is well established, there is still an open question as to whether their different pharmacokinetic and pharmacodynamic characteristics do have a different clinical impact in treating rheumatology patients.

The mechanism related to the anti-inflammatory activity of these drugs is mainly related to the inhibition of the cyclo-oxygenase (COX)-2 isoform, whereas inhibition of COX-1 is associated with the side effects of these drugs. However, some NSAIDs exert their anti-inflammatory and analgesic action by additional mechanisms.

The NSAID nimesulide, along with its preferential activity on COX-2 and a short half-life that correlates with a rapid onset of analgesic action, acts also through a variety of COX-independent pathways that contributes to its potent antiinflammatory and analgesic activity.

The pathways affected by nimesulide include inhibition of tumour necrosis factor alpha (TNF-α) release, histamine release, reactive oxygen species production and chondrocyte death. Furthermore, the use of nimesulide has been associated with reduced levels of matrix metalloproteases and other biomarkers of joint destruction, suggesting it may have a protective effect against disease progression.

Due to its multifactorial mechanism as well as to rapid onset of the analgesic action, nimesulide represents an appealing therapeutic choice for the treatment of rheumatology patients.

Keywords

Ibuprofen Celecoxib Rofecoxib Histamine Release Nimesulide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gotzsche PC. Musculoskeletal disorders. Non-steroidal anti-inflammatory drugs. Clin Evidence 2004; 12: 1702–10Google Scholar
  2. 2.
    Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231: 232–5Google Scholar
  3. 3.
    Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563–8PubMedCrossRefGoogle Scholar
  4. 4.
    Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15PubMedCrossRefGoogle Scholar
  5. 5.
    Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 2006; 5: 75–86PubMedCrossRefGoogle Scholar
  6. 6.
    Kean WF, Buchanan WW. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Inflammopharmacology 2005; 13: 343–70PubMedCrossRefGoogle Scholar
  7. 7.
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520–8PubMedCrossRefGoogle Scholar
  8. 8.
    Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102PubMedCrossRefGoogle Scholar
  9. 9.
    Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081–91PubMedCrossRefGoogle Scholar
  10. 10.
    Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 1481–92PubMedCrossRefGoogle Scholar
  11. 11.
    Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–80PubMedCrossRefGoogle Scholar
  12. 12.
    Sciulli MG, Capone ML, Tacconelli S, et al. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. Pharmacol Rep 2005; 57 (Suppl): 66–85PubMedGoogle Scholar
  13. 13.
    Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644–8PubMedCrossRefGoogle Scholar
  14. 14.
    Shah AA, Thjodleifsson B, Murray FE, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001; 48: 339–46PubMedCrossRefGoogle Scholar
  15. 15.
    Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs — differences and similarities. N Engl J Med 1991; 324: 1716–25PubMedCrossRefGoogle Scholar
  16. 16.
    Bernareggi A. Clinical pharmacokinetics of nimesulide. Clin Pharmacokinet 1998; 35: 247–74PubMedCrossRefGoogle Scholar
  17. 17.
    Herrera JA, Gonzalez M. Comparative evaluation of the effectiveness and tolerability of nimesulide versus rofecoxib taken once a day in the treatment of patients with knee osteoarthritis. Am J Ther 2003; 10: 468–72PubMedCrossRefGoogle Scholar
  18. 18.
    Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000; 38: 225–42PubMedCrossRefGoogle Scholar
  19. 19.
    Depre M, Ehrich E, Van Hecken A, et al. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000; 56: 167–74PubMedCrossRefGoogle Scholar
  20. 20.
    Bennett A, Tavares IA. COX-2 inhibitors compared and contrasted. Expert Opin Pharmacother 2001; 2: 1859–76PubMedCrossRefGoogle Scholar
  21. 21.
    Duffy T, Belton O, Bresnihan B, et al. Inhibition of PGE2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritis. Drugs 2003; 63 (Suppl 1): 31–6PubMedCrossRefGoogle Scholar
  22. 22.
    Bianchi M, Broggini M. A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs 2003; 63 (Suppl 1): 37–46PubMedCrossRefGoogle Scholar
  23. 23.
    Bianchi M, Ferrario P, Balzarini P, et al. Plasma and synovial fluid concentrations of nimesulide and its main metabolite after a single or repeated oral administration in patients with knee osteoarthritis. J Int Med Res 2006; 34: 348–54PubMedGoogle Scholar
  24. 24.
    Rainsford KD and Members of the Consensus Report Group on Nimesulide. Nimesulide’ a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22: 1161–70.PubMedCrossRefGoogle Scholar
  25. 25.
    Azab AN, Kaplanski J. A reduction of tumor necrosis factor-alpha in paw exudate of lipopolysaccharide treated rats by nimesulide. Life Sci 2001; 68: 1667–75PubMedCrossRefGoogle Scholar
  26. 26.
    Ottonello L, Dapino P, Pastorino G, et al. Inhibition of the neutrophil oxidative response induced by the oral administration of nimesulide in normal volunteers. J Clin Lab Immunol 1992; 37: 91–6PubMedGoogle Scholar
  27. 27.
    Dallegri F, Ottonello L, Dapino P, et al. The anti-inflammatory drug nimesulide rescues alpha-1-proteinase inhibitor from oxidative inactivation by phagocytosing neutrophils. Respiration 1992; 59: 1–4PubMedCrossRefGoogle Scholar
  28. 28.
    Rossoni G, Berti F, Buschi A, et al. New data concerning the antianaphylactic and antihistaminic activity of nimesulide. Drugs 1993; 46 (Suppl 1): 22–8PubMedCrossRefGoogle Scholar
  29. 29.
    Saito S, Katoh M, Masumoto M, et al. Involvement of MMP-1 and MMP-3 in collagen degradation induced by IL-1 in rabbit cartilage explant culture. Life Sci 1998; 62: PL 359–65.Google Scholar
  30. 30.
    Wu JJ, Lark MW, Chun LE, et al. Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage. J Biol Chem 1991; 266: 5625–8PubMedGoogle Scholar
  31. 31.
    Kullich WC, Niksic F, Klein G. Effect of nimesulide on metalloproteinases and matrix degradation in osteoarthritis: a pilot clinical study. Int J Clin Pract Suppl 2002: 24–9.Google Scholar
  32. 32.
    Manicourt DH, Bevilacqua M, Righini V, et al. Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis. Drugs R D 2005; 6: 261–71PubMedCrossRefGoogle Scholar
  33. 33.
    Mukherjee P, Rachita C, Aisen PS, et al. Non-steroidal antiinflammatory drugs protect against chondrocyte apoptotic death. Clin Exp Rheumatol 2001; 19 (1 Suppl 22): S7–11PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.First Clinic of Internal MedicineUniversity of Genova Medical SchoolGenovaItaly

Personalised recommendations